Infectious Disease

Take our 5-question quiz to see what you know about these 2 vaccines, the similarities and differences, and how to accommodate both, for now.

A new study finds cases of acute HCV infection increasing on pace with the rise in numbers of opioid abusers who inject drugs. 

It's a short quiz but it covers a broad range of knowledge about testing, treatment, and drug choices in persons with HCV infection.

A community health model based on direct treatment via primary care epxanded detection and treatment of HCV and also increased life expectancy. 

Favorable results seen with sofosbuvir-containing regimens in these complex patients need to be tempered with the high potential for adverse drug interactions.

In this short quiz, we challenge you to choose 4 correct figures and 1 correct fact from your vast store of knowledge on HCV infection.

Read a concise review of a new real-world study that shows high efficacy for this all-oral combination against HCV GT2.

Highlights of 3 studies from 2017 that support the role of PCPs in HCV infection treatment, including prescribing direct-acting antiviral agents.

Clinical trials of second generation direct-acting antivirals in HCV show high cure rates. But do those rates reflect real life?

For PCPs, now poised to play a bigger role in screening and care for patients with HCV, we highlight 10 forces reshaping the HCV landscape.

Flu, shingles, HPV-test a bit of your knowledge on a range of vaccine-preventable diseases.

Injection drug users, pregnant women, men who have sex with men – who needs to be screened for HCV? Click here for the latest recommendations.

Are you up-to-date on HCV? Take this quick quiz and find out.

Here: a quick look at newly approved agents for primary care that will soon be coming your way.

World War I, genotype 3, 25% to 30%, 7 to 9 weeks-see what you know about the numbers related to HCV infection.

A new shingles vaccine could make Zostavax an immunization of the past. Take our short quiz on herpes zoster and shingles prevention.

Here, in plain language, a list of the most common questions you may hear about HCV and the answers, in brief.

Every patient encounter is an opportunity to screen for hepatitis C. Certain women of childbearing age must be included as an at-risk population.

Test your knowledge of the safety events that have occurred involving FDA-approved drugs since the turn of the century.

Eight studies at the 2017 International Liver Congress illuminate the question but the answer is open to interpretation.

Take this brief quiz to see what you’ve learned about the challenges and opportunities of HCV management.

Resistance-associated variants limit the activity of some drugs, but HIV infection treatment may offer some guidance.

Severe outcomes may ensue in a high percentage of patients. The authors discuss the consequences in this brief podcast.

The “modern era” of treatment features multiple DAAs that target specific steps within the HCV life cycle.

State Medicaid programs and private insurance companies have balked at providing these drugs to their insured customers. But the tide is turning.